How to buy Marinus Pharmaceuticals stock - 05 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Marinus Pharmaceuticals stock

Own Marinus Pharmaceuticals stock in just a few minutes.

Posted

Fact checked

Marinus Pharmaceuticals, Inc is a biotechnology business based in the US. Marinus Pharmaceuticals shares (MRNS) are listed on the NASDAQ and all prices are listed in US Dollars. Marinus Pharmaceuticals employs 65 staff and has a trailing 12-month revenue of around USD$171,000.

How to buy shares in Marinus Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Marinus Pharmaceuticals. Find the stock by name or ticker symbol: MRNS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Marinus Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Marinus Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Marinus Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Marinus Pharmaceuticals share price

Use our graph to track the performance of MRNS stocks over time.

Marinus Pharmaceuticals shares at a glance

Information last updated 2021-03-03.
52-week rangeUSD$4.16 - USD$17.14
50-day moving average USD$13.9347
200-day moving average USD$12.7978
Wall St. target priceUSD$28.44
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.982

Buy Marinus Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get two free stock valued between $2.50 and $250
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Marinus Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Marinus Pharmaceuticals financials

Revenue TTM USD$171,000
Gross profit TTM USD$0
Return on assets TTM -55.57%
Return on equity TTM -107.68%
Profit margin 0%
Book value $2.575
Market capitalisation USD$575.2 million

TTM: trailing 12 months

Shorting Marinus Pharmaceuticals shares

There are currently 4.2 million Marinus Pharmaceuticals shares held short by investors – that's known as Marinus Pharmaceuticals's "short interest". This figure is 2% down from 4.3 million last month.

There are a few different ways that this level of interest in shorting Marinus Pharmaceuticals shares can be evaluated.

Marinus Pharmaceuticals's "short interest ratio" (SIR)

Marinus Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Marinus Pharmaceuticals shares currently shorted divided by the average quantity of Marinus Pharmaceuticals shares traded daily (recently around 334098.08306709). Marinus Pharmaceuticals's SIR currently stands at 12.52. In other words for every 100,000 Marinus Pharmaceuticals shares traded daily on the market, roughly 12520 shares are currently held short.

However Marinus Pharmaceuticals's short interest can also be evaluated against the total number of Marinus Pharmaceuticals shares, or, against the total number of tradable Marinus Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Marinus Pharmaceuticals's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Marinus Pharmaceuticals shares in existence, roughly 120 shares are currently held short) or 0.1177% of the tradable shares (for every 100,000 tradable Marinus Pharmaceuticals shares, roughly 118 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Marinus Pharmaceuticals.

Find out more about how you can short Marinus Pharmaceuticals stock.

Marinus Pharmaceuticals share dividends

We're not expecting Marinus Pharmaceuticals to pay a dividend over the next 12 months.

Have Marinus Pharmaceuticals's shares ever split?

Marinus Pharmaceuticals's shares were split on a 1:4 basis on 23 September 2020. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Marinus Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Marinus Pharmaceuticals shares which in turn could have impacted Marinus Pharmaceuticals's share price.

Marinus Pharmaceuticals share price volatility

Over the last 12 months, Marinus Pharmaceuticals's shares have ranged in value from as little as $4.16 up to $17.14. A popular way to gauge a stock's volatility is its "beta".

MRNS.US volatility(beta: 1.57)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Marinus Pharmaceuticals's is 1.5662. This would suggest that Marinus Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Marinus Pharmaceuticals overview

Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors and exhibits anti seizure, antidepressant, and anxiolytic actions through its effects on. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment resistant depression. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site